or to detect CRC at an early, curative stage, which may lead to an improved prognosis and survival [7, 8] . Multiple international societies have endorsed endoscopic surveillance for patients with chronic UC or colonic CD [9] [10] [11] [12] [13] [14] [15] and it has become a cornerstone of IBD-related care, despite paucity of direct evidence for mortality reduction. Understanding the effectiveness of surveillance is crucial: with the increasing incidence of IBD, the costs associated with ongoing surveillance will also continue to rise [16] . Not only are surveillance programs expensive, they result in invasive and recurrent patient interventions that are not without risk.
In a previous meta-analysis, Collins et al. [7] did not demonstrate a statistically significant reduction in CRC-related death in IBD patients undergoing colonoscopy surveillance (pooled relative risk (RR) 0.81 (95% CI: 0.17-3.83)). However, this study was published over a decade ago. Strategies for both IBD management and surveillance have evolved since that time and the introduction of highly effective biologic therapies capable of inducing clinical, endoscopic, and histologic remission in IBD may have altered the natural history of the disease [17] . Currently, the optimal strategy for endoscopic surveillance with respect to timing of colonoscopy, interval between colonoscopies, management of complex lesions using advanced endoscopic resection techniques, and use of chromoendoscopy versus high-definition white light endoscopy (HD-WLE) remains controversial.
In this systematic review and meta-analysis, we update the previous study by Collins et al. [7] . We evaluate the literature with respect to the efficacy of colonoscopy surveillance for CRC detection, stage of CRC diagnosis, and CRC-related mortality in IBD patients with chronic colonic inflammation.
MethodS

Search strategy
We searched MEDLINE , EMBASE (1947 EMBASE ( -2016 , the Cochrane Central Register of Controlled Trials , and the Cochrane IBD Group Specialized Register from inception to 19 September 2016. This was supplemented with hand-searches of reference lists of potentially relevant papers and conference proceedings from Digestive Disease Week, United European Gastroenterology Week, and the European Crohn's and Colitis Organization Congress. The search strategy is detailed in Supplemental Materials and Methods.
Study eligibility criteria
Randomized controlled trials (RCTs) and observational (cohort or case-control) studies evaluating any form of endoscopic surveillance aimed at early detection of CRC in patients of any age with a diagnosis of UC or colonic CD defined by conventional clinical, endoscopic, and histologic criteria selected for surveillance based solely on the duration and extent of disease were eligible for inclusion. Studies without a non-surveillance comparison group were excluded.
Outcomes
The primary outcome was the comparative rate of CRC diagnosis between the surveillance and non-surveillance groups.
Comparative rates of the following secondary outcomes between the surveillance and non-surveillance groups were also evaluated: (1) early-stage (Duke stage [18] A and B) CRC diagnosis; (2) late-stage (Duke stage C and D) CRC diagnosis; (3) colectomy for CRC; and (4) death from CRC. In the original study protocol, time to cancer detection, time to death, and proportion of patients with adverse events (AEs), serious AEs, and study withdrawal due to AEs were a priori defined secondary outcomes; however, the included studies did not sufficiently report these outcomes for inclusion in meta-analysis [19] .
Data extraction
Potentially relevant articles were reviewed independently by three authors (WAB, TMN, CEP) to determine eligibility; disagreements were resolved by consensus. Results from the included studies were then extracted independently by two authors (WAB and TMN) into a standardized extraction form. The proportion of patients dying from CRC in the surveillance and control groups of each study was derived from life tables, survival curves, or where possible, by calculating life tables from the data provided.
Assessment risk of bias and quality of evidence
Methodological quality of each included study was independently evaluated by two authors (WAB and TMN) using the NewcastleOttawa Quality Assessment Scale (NOS) [20] . The NOS uses a star system to assess quality of cohort and case-control studies, with a maximum score of nine stars. For cohort studies, quality is evaluated on three domains: selection of study groups, comparability between the study and control group, and ascertainment of exposure or outcome of interest. For case-control studies, study quality is assessed on selection of study groups, comparability between cases and controls, and ascertainment of exposure.
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the overall quality of evidence supporting the primary and secondary outcomes [21] . Evidence from RCTs is considered high quality and evidence from observational studies is considered low quality; quality of evidence can be downgraded due to risk of bias, indirect evidence, inconsistency/unexplained heterogeneity, imprecision, and publication bias. Overall evidence quality is classified as high, moderate, low, and very low quality. Potential reporting bias was assessed by comparison of outcomes listed in protocols to published manuscripts; if protocols were not available, outcomes listed in the Methods section were compared to those reported in the Results section of published manuscripts. Funnel plots for evaluation of potential publication bias were not constructed due to the small number of included studies (n < 10).
Data synthesis and analysis
For dichotomous outcomes, we calculated the odds ratio (OR) and corresponding 95% CI. Data from individual studies were combined for meta-analysis and the pooled OR and 95% CI was calculated using the Mantel-Haenzel method. Heterogeneity was assessed among studies using the χ 2 test (p value > 0.10 was considered statistically significant) and the I 2 statistic. An I 
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heterogeneity, and 75% indicates high heterogeneity [22] . A fixed effects model was used to pool data unless significant heterogeneity existed between studies; a random-effects model was used if heterogeneity existed (I 2 50-75%). Data were not pooled in metaanalysis if a high degree of heterogeneity (I 2 > 75%) existed. Data analysis was conducted using Review Manager (RevMan 5.3.5).
reSultS
Search results and study characteristics
The literature search identified 12,896 records; 9499 records were screened after removal of duplicates (Fig. 1) . 41 full-text articles were evaluated; most were excluded due to the absence of a nonsurveillance control cohort. No RCTs met criteria for inclusion. Seven reports of five observational studies from 1993 to 2014 were included [23] [24] [25] [26] [27] . Of these five studies, four [23, [25] [26] [27] were cohort studies and one [24] was a case-control design. Four studies [24] [25] [26] [27] were retrospective and one study [23] was prospectively performed. In total, 7199 patients with UC or colonic CD were evaluated. The characteristics of the included studies is summarized in Table 1 and patient characteristics from the included studies are reported in Table 2 .
Cancer detection
Three studies had available data for rates of CRC detection [24, 25, 27] , enrolling 7151 patients (2895 in the surveillance group vs. 4256 in the non-surveillance group). CRC was detected in 53/2895 (1.8%) patients in the surveillance group compared to 135/4256 (3.2%) patients in the non-surveillance group. Using a fixed effects model, surveillance was associated with a 42% reduction in the odds of CRC detection, which was statistically significant (OR 0.58 (95% CI: 0.42-0.80), p < 0.001) (Fig. 2a) . In a sensitivity analysis excluding the most heavily weighted study (Ananthakrishnan et al. [27] ), the magnitude and direction of effect of surveillance colonoscopy on CRC detection was similar, but the results were no longer statistically significant (OR 0.67 (95% CI: 0.30-1.50)).
CRC-related death
Death due to CRC was reported in 4 studies [23, [25] [26] [27] , enrolling 530 patients (176 in the surveillance group vs. 354 in the non-surveillance group). CRC-related death occurred in 8.5% (15/176) of patients in the surveillance group compared to 22.3% (79/354) of patients in the non-surveillance group. Using a fixed effects model, surveillance was associated with a 64% reduction in the odds of CRC-related death, which was statistically significant (OR 0.36 (95% CI: 0.19-0.69), p = 0.002) (Fig. 2b) . This effect was maintained even in sensitivity analysis excluding the study by Ananthakrishnan et al. [27] (OR 0.40 (95% CI: 0.17-0.95)).
Tumor stage
Two studies had available data to examine detection of early-and late-stage CRC [23, 25] (Table 3) . A higher rate of early-stage CRC was detected in the surveillance group (15.5%, 17/110) compared to the non-surveillance group (7.7%, 9/117) using a fixed effects model (OR 5.40 (95% CI: 1.51-19.30), p = 0.009) (Fig. 2c) , which was statistically significant. In comparison, there was a nominally but not statistically significant lower rate of detection of late-stage CRC in patients undergoing surveillance (9.1%, 10/110) compared to patients not undergoing surveillance (16.2%, 19/117) (OR 0.46 (95% CI: 0.08-2.51), p = 0.37); a random-effects model was used for this analysis due to significant heterogeneity (I 2 = 71%) (Fig. 2d) . One study [26] described CRC stage at diagnosis using the American Joint Committee on Cancer 6th Edition Tumor Node Metastasis (TNM) staging system: surveillance was associated with a higher rate of diagnosing stage 1 CRC compared to non-surveillance (43.5%, 10/23 vs. 15.7%, 19/121, p = 0.008).
Colectomy
In one study, surveillance was associated with a lower risk of colectomy (36.3%, 33/91) compared to non-surveillance (53.7%, 51/95) (OR 0.49 (95% CI: 0.27-0.88)) [25] .
Risk of bias and quality of evidence
The risk of bias in the five included non-randomized trials was assessed using the NOS; all studies scored well based on selection of study groups, comparability between intervention and control group, and outcome and exposure ascertainment (Supplemental Table 1 ). A GRADE analysis indicated that the quality of evidence supporting the outcomes of cancer detection, CRC-related death, and tumor stage was very low due to the observational nature of the included studies and imprecision of the effect estimates. No potential reporting bias was detected.
dIScuSSIon
As the incidence of IBD increases worldwide, a greater resource burden will be placed on endoscopic surveillance programs for CRC detection [16] . A prospective, long-term, RCT directly assessing survival benefit with endoscopic surveillance in IBD patients would be challenging to perform due to low event rates; thus, the best available evidence arises from observational data. Recognizing the inherent limitations of observational studies for drawing conclusions regarding causality, we updated a previous Cochrane systematic review and meta-analysis to evaluate the impact of surveillance colonoscopy on detection of CRC and death attributable to CRC in IBD patients. This updated review suggests that the ongoing use of colonoscopy surveillance may reduce both CRC development and CRC-associated death through detection of early-stage cancers. Although the quality of evidence is very low, an RCT that answers these questions is unlikely to be performed, particularly given the ethical considerations precluding randomization of IBD patients to a non-surveillance arm. Thus, we consider this pooled analysis to be the best available evidence at present to inform the benefit of colonoscopic surveillance.
Drawing conclusions regarding causality are limited by potential confounding bias in the included observational studies. Most authors attempted to control for confounders such as patient age and disease duration in multivariable logistic or Cox regression models ( Table 1) . However, important covariates such as concomitant therapy, disease phenotype, and frequency of assessments were not always adjusted for ( Table 2 ). The largest study in this meta-analysis by Ananthakrishnan et al. [27] included 6823 IBD patients: the authors retrospectively examined the effect of colonoscopy within 6-36 months of CRC diagnosis (for cases) or end of follow-up (for controls) in a well-validated electronic IBD database capturing two tertiary care referral centers. In sensitivity analyses excluding this study, our conclusions of a significant benefit to surveillance colonoscopy on mortality were unchanged and surveillance was associated with a 33% non-statistically significant reduction in CRC detection. Ananthakrishnan et al. [27] further demonstrated the beneficial effect of surveillance colonoscopy which was robust even after adjusting for disease phenotype, extent, primary sclerosing cholangitis, erythrocyte sedimentation rate, follow-up duration, and intensity of health care utilization.
Since IBD-associated CRC is postulated to arise from precursor dysplasia [28] , the theoretical benefit of surveillance colonoscopy is to detect and remove dysplasia, either endoscopically or surgically, prior to the development of CRC. Screening programs for sporadic CRC leverage the therapeutic window between the onset of dysplasia and development of CRC as an opportunity for endoscopic removal of pre-cancerous lesions [29] . Carcinogenesis in sporadic CRC typically results from the "adenoma-carcinoma sequence", with the progressive accumulation of somatic mutations 
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in a dysplastic focus; this process can take years and can be arrested by endoscopic polypectomy [30] . This surveillance model may not translate to the IBD population. First, strategies and tools for dysplasia detection in IBD patients have evolved substantially. Previous recommendations for random four-quadrant biopsies every 10 cm have come under scrutiny with multiple studies demonstrating that targeted biopsies may be more effective for dysplasia detection than random biopsies [31] [32] [33] . Second, chromoendoscopy may be superior to white light endoscopy for dysplasia detection [15] . However, this was informed by studies conducted before widespread use of HD-WLE and a recent RCT of HD-WLE versus chromoendoscopy demonstrated no significant difference in dysplasia or neoplasia detection [34] . Three studies included in our meta-analysis specified the use of random four-quadrant biopsy surveillance and none identified the use of either HD-WLE or chromoendoscopy. Updated studies evaluating the efficacy of these different strategies on CRC detection and mortality are required.
Although dysplasia detection is an important surrogate for future CRC risk, it does not necessarily confer improved quality of life or increased survival in patients with IBD. While resecting polypoid dysplasia is associated with low future CRC risk [35] , it does not obviate the high risk of CRC associated with invisible dysplasia or non-polypoid dysplasia [36] . This highlights the difference in tumorigenesis in patients with IBD compared to sporadic CRC. In IBD, chronic inflammation with repeated epithelial wounding and repair results in selection for mutant clones resistant to apoptosis and with accelerated growth better suited to a hostile microenvironment [37] . Not only does this predispose to synchronous lesions but it also renders large areas of the colonic mucosa genetically unstable ("field cancerization") [38] . Resection of circumscribed focal dysplastic lesions does not address the underlying predisposition to cancer development in histologically inflamed tissue and may not mitigate future CRC risk [39, 40] .
Despite these challenges, we demonstrate in this meta-analysis that surveillance colonoscopy is associated with a decrease in both CRC development and death secondary to CRC. This mirrors epidemiologic data that suggests the incidence of IBD-associated CRC is decreasing, although this cannot be causally attributed to surveillance programs since other factors may influence this, such as better treatments to control inflammation. Initial estimates of cumulative CRC risk in UC patients were as high as 2% at 10 years, 8% at 20 years, and 18% at 30 years of disease [1] . This risk has been recently downgraded: in a meta-analysis of nine populationbased studies, Lutgens et al. [41] report a SIR for IBD-associated CRC of 1.7 (95% CI: 1.2-2.2) [41] . Advances in endoscopic surveillance and dysplasia detection are postulated mechanisms contributing to this decrease in CRC incidence. However, enhanced medical therapies for control of active inflammation and possible chemoprophylaxis protection from 5-aminosalicylates are potential confounders [42] .
Although the incidence of IBD-associated CRC may be decreasing, the number of patients undergoing surveillance is increasing due to the rising incidence of IBD [16] . Given the substantial financial and resource costs associated with colonoscopy, identifying IBD patients at highest risk for CRC development for targeting screening is critical. Current guidelines for the timing of surveillance colonoscopy are primarily based on disease extent and duration which are demonstrated risk factors for IBD-associated CRC [37] . Other risk factors for IBD-associated CRC include increasing age, male sex, and strong family history [43] . However, these are relatively crude predictors for identifying specific patients who would benefit from surveillance. Future research should focus on improving the precision of CRC risk estimation, potentially through incorporation of less invasive tests such as fecal DNA testing or rectal mucosal fluorescence in situ hybridization analysis for chromosomal instability [44] . Fecal immunochemical testing has been adopted for sporadic CRC screening in average risk populations; however, its application to IBD patients is limited by false positives due to detection of fecal hemoglobin from mucosal ulcerations in active inflammation [45] . The effect of surveillance colonoscopy on colectomy was investigated by Lashner et al. [25] , who reported significantly lower rates of colectomy for CRC, dysplasia, or active disease (OR 0.49 (95% CI: 0.27-0.88), p = 0.02) in patients receiving surveillance colonoscopy compared to those in the non-surveillance group [25] . However, these results should be re-examined given that endoscopic techniques for both lesion identification and excision have advanced significantly since this study. Furthermore, a finding of dysplasia no longer absolutely necessitates colectomy. Indeed, in patients with invisible low-grade dysplasia, the decision for ongoing surveillance colonoscopy versus colectomy as the most cost-effective management strategy is dependent on multiple factors including age, comorbidity, and expected postoperative morbidity [46] .
Our study has several limitations. First and most importantly, no RCTs were eligible for inclusion which limited the quality of evidence synthesis in GRADE analysis. However, RCTs that directly Total (95% Cl) Heterogeneity: 2 = 3.86, df = 2 (P = 0.14); I 2 = 48% Test for overall effect: Z = 3.31 (P = 0.0009) Heterogeneity: 2 = 5.01, df = 3 (P = 0.17); I 2 = 40% Test for overall effect: Z = 3.12 (P = 0.002) Heterogeneity: 2 = 0.00, df = 1 (P = 0.99); I 2 = 0% Test for overall effect: Z = 2.59 (P = 0.009) Heterogeneity: 2 = 1.08; 2 = 3.50, df = 1 (P = 0.06); I 2 = 71% Test for overall effect: Z = 0.90 (P = 0.37) 
evaluate the effect of colonoscopy surveillance on CRC in IBD patients are unlikely to ever be performed due to ethical and logistical considerations. Even retrospective studies that evaluate this question are difficult to perform because the pool of IBD patients not undergoing surveillance is limited. Second, limitations of the included studies need to be considered when interpreting pooled results from meta-analysis. Such limitations include: (1) the potential for volunteer bias among patients seeking out surveillance colonoscopy; (2) possible referral bias when data are derived from tertiary care centers that treat a higher prevalence of patients with refractory or severe disease; and (3) heterogeneous surveillance practices with respect to interval of repeat surveillance colonoscopy and biopsy strategy, Although we included all studies evaluating endoscopic surveillance, there were insufficient data to compare different surveillance strategies, and comparative studies of HD-WLE, chromoendoscopy, and digital image enhancement colonoscopy are needed. Third, we evaluated the effect of surveillance on stage of CRC diagnosis by the Duke staging system; this has largely been replaced by the American Joint Committee on Cancer TNM staging system [47] . However, many of the included studies were published before the TNM system was widely adopted and both classifications have distinct similarities with respect to depth of tumor penetration. Fourth, we did not evaluate the effect of polypectomy on mortality as it was outside the scope of this review. However, additional data linking dysplasia detection and endoscopic resection to reduction in IBD-associated CRC outcomes are needed.
In conclusion, in this Cochrane systematic review and metaanalysis, we demonstrate in pooled analysis from observational studies that colonoscopy surveillance results in a reduction in IBDassociated CRC development by 42% and CRC-associated death by 64% compared to patients who do not undergo surveillance. We speculate that this reduction in CRC-associated death is due to increased detection of early-stage cancers associated with better prognosis. Updated studies are required to evaluate the benefits of modern surveillance techniques, including advancements in endoscopic technology and dysplasia resection. We further hypothesize that additional benefits may be derived from surveillance: as therapeutic targets for both UC and CD shift from symptom resolution towards normalization of histologic and endoscopic endpoints, surveillance colonoscopy offers a further opportunity to tailor treatment towards targeting more robust objective outcomes and improve long-term disease prognosis.
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WHAT IS NEW HERE
✓ In this contemporary systematic review and meta-analysis, we identified five relevant observational studies enrolling 7199 IBd patients, but no randomized controlled trials.
✓ on pooled analysis, a 42% reduction in the odds of crc with surveillance colonoscopy was observed.
✓ on pooled analysis, a 64% reduction in the odds of crcrelated death with surveillance colonoscopy was observed.
✓ A greater than 5-fold increase in the odds of early stage crc detection with surveillance colonoscopy. referenceS
